View Item 

Show simple item record

Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)
dc.contributor.authorRossing, Peter
dc.contributor.authorGarweg, Justus G.
dc.contributor.authorAnker, Stefan D.
dc.contributor.authorOsonoi, Takeshi
dc.contributor.authorPitt, Bertram
dc.contributor.authorRosas, Sylvia E.
dc.contributor.authorRuilope, Luis Miguel
dc.contributor.authorZhu, Dalong
dc.contributor.authorBrinker, Meike
dc.contributor.authorFinis, David
dc.contributor.authorLeal, Sergio
dc.contributor.authorSchmelter, Thomas
dc.contributor.authorBakris, George
dc.date.accessioned2023-03-03T21:09:35Z
dc.date.available2024-04-03 16:09:34en
dc.date.available2023-03-03T21:09:35Z
dc.date.issued2023-03
dc.identifier.citationRossing, Peter; Garweg, Justus G.; Anker, Stefan D.; Osonoi, Takeshi; Pitt, Bertram; Rosas, Sylvia E.; Ruilope, Luis Miguel; Zhu, Dalong; Brinker, Meike; Finis, David; Leal, Sergio; Schmelter, Thomas; Bakris, George (2023). "Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)." Diabetes, Obesity and Metabolism 25(3): 894-898.
dc.identifier.issn1462-8902
dc.identifier.issn1463-1326
dc.identifier.urihttps://hdl.handle.net/2027.42/175909
dc.publisherBlackwell Publishing Ltd
dc.publisherWiley Periodicals, Inc.
dc.subject.otherdiabetic retinopathy
dc.subject.otherphase III study
dc.subject.otherrandomized trial
dc.subject.othertype 2 diabetes
dc.titleEffect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175909/1/dom14915.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175909/2/dom14915_am.pdf
dc.identifier.doi10.1111/dom.14915
dc.identifier.sourceDiabetes, Obesity and Metabolism
dc.identifier.citedreferenceWilkinson-Berka JL, Tan G, Jaworski K, Harbig J, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res. 2009; 104 ( 1 ): 124 - 133.
dc.identifier.citedreferencePark HC, Lee YK, Cho A, et al. Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. PLoS One. 2019; 14 ( 7 ): e0220506.
dc.identifier.citedreferenceWang B, Wang F, Zhang Y, et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015; 3 ( 4 ): 263 - 274.
dc.identifier.citedreferenceMansour SE, Browning DJ, Wong K, Flynn HW Jr, Bhavsar AR. The evolving treatment of diabetic retinopathy. Clin Ophthalmol. 2020; 14: 653 - 678.
dc.identifier.citedreferenceWong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the International Council of Ophthalmology Recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018; 125 ( 10 ): 1608 - 1622.
dc.identifier.citedreferenceRuilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019; 50 ( 5 ): 345 - 356.
dc.identifier.citedreferenceBakris GL, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019; 50 ( 5 ): 333 - 344.
dc.identifier.citedreferencePitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021; 385: 2252 - 2263.
dc.identifier.citedreferenceBakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020; 383 ( 23 ): 2219 - 2229.
dc.identifier.citedreferenceWilkinson-Berka JL, Suphapimol V, Jerome JR, Deliyanti D, Allingham MJ. Angiotensin II and aldosterone in retinal vasculopathy and inflammation. Exp Eye Res. 2019; 187: 107766.
dc.identifier.citedreferenceFusi-Rubiano W, Saedon H, Patel V, Yang YC. Oral medications for central serous chorioretinopathy: a literature review. Eye. 2020; 34 ( 5 ): 809 - 824.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
dom14915.pdf
Size:
757.0KB
Format:
PDF
View/Open
Name:
dom14915_am.pdf
Size:
766.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.